BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20826047)

  • 1. Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model.
    Stannard KA; Collins PM; Ito K; Sullivan EM; Scott SA; Gabutero E; Darren Grice I; Low P; Nilsson UJ; Leffler H; Blanchard H; Ralph SJ
    Cancer Lett; 2010 Dec; 299(2):95-110. PubMed ID: 20826047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varied expression and localization of multiple galectins in different cancer cell lines.
    Satelli A; Rao PS; Gupta PK; Lockman PR; Srivenugopal KS; Rao US
    Oncol Rep; 2008 Mar; 19(3):587-94. PubMed ID: 18288388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectins as markers of aggressiveness of mouse mammary carcinoma: towards a lectin target therapy of human breast cancer.
    Moiseeva EV; Rapoport EM; Bovin NV; Miroshnikov AI; Chaadaeva AV; Krasilshschikova MS; Bojenko VK; Bijleveld C; van Dijk JE; Den Otter W
    Breast Cancer Res Treat; 2005 Jun; 91(3):227-41. PubMed ID: 15952056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer.
    Irie A; Yamauchi A; Kontani K; Kihara M; Liu D; Shirato Y; Seki M; Nishi N; Nakamura T; Yokomise H; Hirashima M
    Clin Cancer Res; 2005 Apr; 11(8):2962-8. PubMed ID: 15837748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins.
    Sioud M; Mobergslien A; Boudabous A; Fløisand Y
    Int J Oncol; 2011 Feb; 38(2):385-90. PubMed ID: 21165555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thermodynamic binding studies of galectin-1, -3 and -7.
    Brewer CF
    Glycoconj J; 2002; 19(7-9):459-65. PubMed ID: 14758069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice.
    Demotte N; Wieërs G; Van Der Smissen P; Moser M; Schmidt C; Thielemans K; Squifflet JL; Weynand B; Carrasco J; Lurquin C; Courtoy PJ; van der Bruggen P
    Cancer Res; 2010 Oct; 70(19):7476-88. PubMed ID: 20719885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural analysis of the human galectin-9 N-terminal carbohydrate recognition domain reveals unexpected properties that differ from the mouse orthologue.
    Nagae M; Nishi N; Nakamura-Tsuruta S; Hirabayashi J; Wakatsuki S; Kato R
    J Mol Biol; 2008 Jan; 375(1):119-35. PubMed ID: 18005988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-loaded cells as a platform for the profiling of lectin specificity by fluorescent neoglycoconjugates: a case study on galectins-1 and -3 and the impact of assay setting.
    Rapoport EM; André S; Kurmyshkina OV; Pochechueva TV; Severov VV; Pazynina GV; Gabius HJ; Bovin NV
    Glycobiology; 2008 Apr; 18(4):315-24. PubMed ID: 18256179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation into the feasibility of thioditaloside as a novel scaffold for galectin-3-specific inhibitors.
    Bum-Erdene K; Gagarinov IA; Collins PM; Winger M; Pearson AG; Wilson JC; Leffler H; Nilsson UJ; Grice ID; Blanchard H
    Chembiochem; 2013 Jul; 14(11):1331-42. PubMed ID: 23864426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence.
    Luo Y; Zhou H; Mizutani M; Mizutani N; Liu C; Xiang R; Reisfeld RA
    Cancer Res; 2005 Apr; 65(8):3419-27. PubMed ID: 15833877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
    Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag.
    Felicetti P; Mennecozzi M; Barucca A; Montgomery S; Orlandi F; Manova K; Houghton AN; Gregor PD; Concetti A; Venanzi FM
    Cytotherapy; 2007; 9(1):23-34. PubMed ID: 18236207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
    Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
    Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regioselective 3-O-Substitution of Unprotected Thiodigalactosides: Direct Route to Galectin Inhibitors.
    Vašíček T; Spiwok V; Červený J; Petrásková L; Bumba L; Vrbata D; Pelantová H; Křen V; Bojarová P
    Chemistry; 2020 Aug; 26(43):9620-9631. PubMed ID: 32368810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Listeria monocytogenes activated dendritic cell based vaccine for prevention of experimental tumor in mice.
    Khamisabadi M; Arab S; Motamedi M; Khansari N; Moazzeni SM; Gheflati Z; Hadjati J
    Iran J Immunol; 2008 Mar; 5(1):36-44. PubMed ID: 18319523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorescence polarization as an analytical tool to evaluate galectin-ligand interactions.
    Sörme P; Kahl-Knutsson B; Huflejt M; Nilsson UJ; Leffler H
    Anal Biochem; 2004 Nov; 334(1):36-47. PubMed ID: 15464951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
    Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J
    Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.